Introduction Osimertinib is a standard first-line treatment for non–small cell lung cancer
(NSCLC) harboring mutations of the epidermal growth factor receptor gene (EGFR) …

The identification of epidermal growth factor receptor (EGFR) mutations represented a
fundamental step forward in the treatment of advanced non-small cell lung cancer (NSCLC) …

Patients with advanced epidermal growth factor receptor (EGFR) mutant non-small cell lung
cancer (NSCLC) are particularly sensitive to treatment with first-or second-generation EGFR …

First-and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung …

© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2018; 7
(Suppl 2): S134-S137 tlcr. amegroups. com the Lancet Oncol by Wu et al., is a phase III …

First generation or second generation EGFR tyrosine kinase inhibitors are currently the
standard of care for the first-line management of non-small cell lung cancer (NSCLC) …

Data from the AURA phase II extension component confirms the high activity of osimertinib
at 80 mg oncedaily in patients with EGFRm NSCLC progressing after EGFR-TKI treatment …

Importance The survival of patients with advanced non–small cell lung cancer (NSCLC) with
epidermal growth factor receptor (EGFR) gene mutations has improved substantially in the …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI s) are the first‐line
treatment for patients with EGFR mutant non‐small‐cell lung cancer (NSCLC). However …

The FLAURA trial established osimertinib, a third-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell …